Liver Damage and Impaired Coagulation in COVID-19 Patients: A Case Series.
SARS-CoV-2
histology
inflammation
liver disease
vascular disease
Journal
Diseases (Basel, Switzerland)
ISSN: 2079-9721
Titre abrégé: Diseases
Pays: Switzerland
ID NLM: 101636232
Informations de publication
Date de publication:
13 Oct 2023
13 Oct 2023
Historique:
received:
01
09
2023
revised:
02
10
2023
accepted:
12
10
2023
medline:
24
10
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has generated an unprecedented challenge for healthcare systems worldwide. Currently, the scientific community wonders if liver injury in patients suffering from severe forms is a direct consequence of the virus or secondary manifestations of systemic inflammation. The liver plays an essential role in the development of the inflammatory storm typical of this disease, and its involvement is associated with worse clinical outcomes and a higher risk of morbidity and mortality from Coronavirus disease 2019 (COVID-19). Ten patients suffering from severe COVID-19 disease who died between January 2020 and December 2021 were included in the present analysis. These subjects underwent a post mortem examination with a focused evaluation of the hepatic injury. Also, several laboratory parameters have been evaluated, with a primary focus on prothrombin time, partial thromboplastin time, fibrinogen, antithrombin III, and D-dimers to detect coagulative changes. The main cause of death was represented by pulmonary thromboembolism events (50%). The analysis of coagulation laboratory parameters and liver biomarkers revealed a statistically significant rise in aPTT and ALP, and a decrease in albumin, when comparing the blood value at admission and death. We also found high levels of D-dimers in most of the subjects at the time of hospitalization. Interestingly, the post mortem analysis of the liver showed ample morphologic variability, with several disease features. In detail, the liver histology revealed the following: the presence of a variable degree of micro- and macrovacuolar steatosis, inflammation (also, hepato-cholangitis), and variable fibrosis. Of mention, we were also able to detect organized fibrinous material. Our results indicate that in subjects with a severe form of COVID-19, liver disease is related to changes in coagulative and fibrinolytic pathways. In particular, we noted low fibrinogen levels and high D-dimer levels with histological liver findings. Our data suggest that fibrinogen and D-dimers may be used as prognostic markers to detect the severity of liver disease in patients with COVID-19. Finally, we underline the crucial role of coagulation balance in subjects with severe forms of COVID-19.
Identifiants
pubmed: 37873785
pii: diseases11040141
doi: 10.3390/diseases11040141
pmc: PMC10594514
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Thromb Haemost. 2020 Jun;120(6):998-1000
pubmed: 32316063
J Intern Med. 2021 Aug;290(2):470-472
pubmed: 33786906
Int J Mol Sci. 2020 Jul 21;21(14):
pubmed: 32708334
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Curr Issues Mol Biol. 2023 Apr 04;45(4):3035-3047
pubmed: 37185723
Int J Gen Med. 2021 Jun 24;14:2785-2797
pubmed: 34194238
Arch Med Sci Atheroscler Dis. 2023 Feb 23;8:e1-e10
pubmed: 37153375
Biosens Bioelectron. 2021 Jan 15;172:112752
pubmed: 33126180
Int J Mol Sci. 2021 Apr 26;22(9):
pubmed: 33925831
Rev Recent Clin Trials. 2021;16(3):309-315
pubmed: 33797377
World J Gastroenterol. 2022 Feb 7;28(5):570-587
pubmed: 35316959
Front Immunol. 2021 Jul 07;12:708264
pubmed: 34305949
J Biomed Sci. 2022 Oct 26;29(1):87
pubmed: 36289507
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Minerva Gastroenterol (Torino). 2023 Mar;69(1):141-148
pubmed: 35470356
Cells. 2021 Jul 11;10(7):
pubmed: 34359922
Liver Int. 2021 Sep;41(9):1988-1998
pubmed: 34152690
J Clin Transl Hepatol. 2020 Jun 28;8(2):0024
pubmed: 32309152
Mod Pathol. 2015 Jul;28(7):932-43
pubmed: 25793895
Emerg Med J. 2022 Jan;39(1):63-69
pubmed: 34548413
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
PLoS One. 2017 Jun 1;12(6):e0178473
pubmed: 28570615
J Microbiol Immunol Infect. 2021 Apr;54(2):159-163
pubmed: 32265180
Int J Environ Res Public Health. 2021 Jan 31;18(3):
pubmed: 33572570
Liver Int. 2020 Sep;40(9):2110-2116
pubmed: 32654359
Mod Pathol. 2021 Aug;34(8):1456-1467
pubmed: 33795830
Minerva Med. 2021 Feb;112(1):144-152
pubmed: 33104300
J Clin Pathol. 2020 May;73(5):239-242
pubmed: 32198191
Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):5904-5912
pubmed: 34661248
Clin Microbiol Infect. 2021 Mar;27(3):389-395
pubmed: 33359375
J Clin Pathol. 2021 Nov;74(11):750-751
pubmed: 33067181
Rev Recent Clin Trials. 2021;16(2):138-145
pubmed: 32940187
Sci Rep. 2022 Aug 1;12(1):13155
pubmed: 35915103
Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):217-221
pubmed: 32306655
Br J Anaesth. 2020 Sep;125(3):238-242
pubmed: 32731958
Minerva Gastroenterol (Torino). 2021 Sep;67(3):283-288
pubmed: 33971711
Thromb Res. 2021 Feb;198:139-150
pubmed: 33340925
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Hepatol Res. 2021 Feb;51(2):227-232
pubmed: 33047431
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Arch Pathol Lab Med. 2020 Nov 1;144(11):1298-1302
pubmed: 32589448
Signal Transduct Target Ther. 2021 Jul 7;6(1):255
pubmed: 34234112
World J Gastroenterol. 2022 Mar 21;28(11):1102-1112
pubmed: 35431501
World J Gastroenterol. 2023 Jan 14;29(2):367-377
pubmed: 36687116
Abdom Radiol (NY). 2020 Sep;45(9):2748-2754
pubmed: 32683613
Minerva Gastroenterol Dietol. 2020 Jun;66(2):90-92
pubmed: 32221278